Aptiv Solutions, as DS Healthcare's CRO, will prepare the company's Investigational New Drug Application (IND) for its proprietary topical hair loss treatment, for submission to the FDA. To date, only one other topical treatment for hair loss has been approved by the FDA. Aptiv Solutions will also conduct a Gap analysis to ensure that DS Healthcare's operations are in line with regulatory requirements for drug approval.

You can read the full release here.